Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian specialty pharmaceutical company, Paladin Labs has completed the acquisition of all of the outstanding common shares of Labopharm.
Subscribe to our email newsletter
Paladin Labs is focused on in-licensing pharmaceutical products for the Canadian and world markets.
Paladin Labs interim president and CEO Mark Beaudet said the acquisition of Labopharm will add established international revenue streams besides providing the opportunity to build upon their existing operational capabilities.
"Moreover, Labopharm’s worldwide partnerships provide us with an exciting opportunity to continue cultivating important relationships internationally," Beaudet added.